Lytix Biopharma ASA
OOSL:LYTIX7.82
NOK
-0.14
(-1.76%)
Lytix Biopharma ASA
OSL:LYTIX
(Euronext Oslo)
Recent
price
7.82
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
NOK
•
in mil. unless spec.Working Capital
NOK
•
in mil. unless spec.Growth Rates
NOK
•
in mil. unless spec.Quarterly Revenue
NOK
•
in mil. unless spec.Quarterly Earnings Per Share
NOK
•
in mil. unless spec.Quarterly Dividends Per Share
NOK
•
in mil. unless spec.- Similar Companies
- Business
- Lytix Biopharma AS, a clinical-stage biotechnology company founded in 2003 and headquartered in Oslo, Norway, develops novel cancer immunotherapies based on host-defense peptide-derived molecules that selectively kill cancer cells and activate the patient's immune system. The company's lead product candidate, ruxotemitide (formerly LTX-315), is an oncolytic peptide in Phase II clinical trials for indications including neoadjuvant melanoma, basal cell carcinoma, and other solid tumors; it functions by inducing immunogenic cell death, promoting tumor infiltration by lymphocytes, and serving as a source of patient-specific antigens for sustained immune responses. Additional pipeline assets include LTX-401, a proprietary molecule in late preclinical development targeting deep-seated tumors, with strategic plans for clinical advancement informed by positive regulatory feedback. Lytix grants exclusive licenses for its technologies, such as the 2020 royalty-bearing agreement with Verrica Pharmaceuticals Inc. for ruxotemitide development, manufacturing, and commercialization in non-melanoma skin cancers. Operations focus on the biopharmaceutical sector, primarily serving patients with advanced solid tumors through collaborations with international research institutions, hospitals, and partners in the United States and Europe. Recent developments include positive Phase II data for ruxotemitide announced post-Q3 2025, featuring a 97% objective response rate and 51% complete histologic clearance in basal cell carcinoma from Verrica's study, alongside 88% overall pathological response in neoadjuvant melanoma with no relapses reported; these results prompted acceleration of the development strategy toward Phase III trials. In December 2024, Lytix raised NOK 100 million and EUR 1 million through a directed share issue and primary bid offering to fund milestones, extending runway into 2026, while Verrica secured USD 40 million for its programs including potential basal cell carcinoma Phase III. Q3 2025 financials reflected a net loss of NOK 11.5 million amid pipeline progress, with ongoing investigator-sponsored NeoLIPA trial recruitment in neoadjuvant melanoma combined with PD-1 inhibitors and openness to new partnerships for global expansion.